Mar 02, 2026 / 12:30PM GMT
Presentation Review
Mar 02, 2026 / 12:30PM GMT
=====================
Corporate Participants
=====================
* Bill Slattery Jr
Ocular Therapeutix Inc - Vice President, Investor Relations
* Pravin Dugel
Ocular Therapeutix Inc - Executive Chairman of the Board, President, Chief Executive Officer
* Jeffrey Heier
Ocular Therapeutix Inc - Chief Scientific Officer
* Peter Kaiser
Ocular Therapeutix Inc - Chief Development Officer
=====================
Conference Call Participants
=====================
* Tazeen Ahmad
Bank of America - Analyst
* Biren Amin
Piper Sandler - Analyst
* Colleen Kusy
Robert W. Baird & Co Inc - Analyst
* Sean McCutcheon
Raymond James - Analyst
* Lisa Walter
RBC Capital Markets Inc - Equity Analyst
* Clara Dong
Jefferies LLC - Equity Analyst
* Jon Wolleben
Citizens JMP - Analyst
* Yi Chen
H.C. Wainwright - Analyst
* Lachlan Hanbury-Brown
William
Ocular Therapeutix Inc
(STU:0OT)
€
7.1
-0.20 (-2.74%)
Market Cap: 1.55 Bil
Enterprise Value: 1.04 Bil
PE Ratio: 0
PB Ratio: 3.07
GF Score: 57/100 Ocular Therapeutix Inc SOL-1 Macula Society Presentation Review Transcript
Mar 02, 2026 / 12:30PM GMT
Release Date Price:
€7.53
(+0.08%)
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot